All In Biotech

Drug Trial Radar · NCT00453336

Photodynamic Therapy With Porfimer Sodium in Treating Patients With Precancerous Lesions, Cancer, or Other Disease of the Aerodigestive Tract

A Phase II Clinical Trial on the Efficacy of Photodynamic Therapy With Porfimer Sodium (Photofrin®) for Malignant and Pre-Malignant Lesions and Condemned Mucosa Syndrome in the Upper Aerodigestive Tract

Last checked: Nov 19, 2026Latest source record: Feb 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

45

Actual

Start

Jun 2003

Primary completion

Aug 2009

Study completion May 2010

Sponsor

Lead sponsor
University of MiamiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 28, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, precancerous cells and cancer cells are killed. PURPOSE: This phase II trial is studying the side effects and how well photodynamic therapy with porfimer sodium works in treating patients with precancerous lesions, cancer, or other disease of the aerodigestive tract.

Conditions

  • Head and Neck Cancer
  • Precancerous/Nonmalignant Condition

Interventions

  • Porfimer SodiumDrug

    Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.

  • Photodynamic TherapyProcedure

    Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Achieving Complete or Partial Response 4 Months After Completion of Study TreatmentTime frame: 6 months
  2. Number of Participants Experiencing Adverse EventsTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Miami Sylvester Comprehensive Cancer Center - Miami

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.